NanoViricides Reports Progress on NV-387 in Latest SEC Filing

NanoViricides, Inc. has submitted its Quarterly Report for the quarter ending March 31, 2026. The company is advancing NV-387, a broad-spectrum antiviral drug, towards a Phase II clinical trial in the Democratic Republic of Congo for Monkeypox treatment, with local regulatory approval already granted. NanoViricides has sought orphan drug designation from the US FDA for NV-387 to treat Measles, MPox, and Smallpox. An orphan drug designation can provide several incentives including market exclusivity and tax benefits.

The company aims to address unmet medical needs with NV-387, deemed highly active against various viruses in preclinical trials. Financials indicate a cash balance of $3.38 million as of March 31. While focused on progressing the MPox trial, the company acknowledges the need for additional funding to support broader clinical aims. NanoViricides anticipates that its regulatory strategy will facilitate swift approval pathways and potentially significant funding opportunities.